Vnitr Lek 2016, 62(Suppl 4):113-118

Should we consider a new classification of diabetes influenced by therapeutic decisions?

Jan Škrha
III. interní klinika 1. LF UK a VFN v Praze

The growing number of diabetic patients in the whole world causes the problems to allocate some patients into the respective type of diabetes related to the present classification. B cell is considered as the central cause of diabetes and its intracellular impairment is practically the same in both types of diabetes. Diabetic patients will be recognized according to the state of impaired B cell. The antidiabetic drugs will be selected according to their effect protecting the B cells. Some antidiabetic drugs will be used more frequently in type 1 diabetes as well.

Keywords: antidiabetic drugs protecting B cell; B cell apoptosis; diabetes classification

Received: July 14, 2016; Accepted: September 26, 2016; Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Should we consider a new classification of diabetes influenced by therapeutic decisions? Vnitr Lek. 2016;62(Supplementum 4):113-118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Škrha J. Cesta diabetologie aneb jak vše začíná a končí? Maxdorf: Praha 2014. ISBN 978-80-7345-385-5.
    2. Wang X, Tan H. Male predominance in ketosis-prone diabetes mellitus (Review). Biomed Rep 2015; 3(4): 439-442. Go to original source... Go to PubMed...
    3. Jha S, Waghdhare S, Siddiqui S et al. First Identification of Flatbush Diabetes in Patients of Indian Origin. Diabetes Care 2015; 38(12): e164-e165. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-1209>. Go to original source... Go to PubMed...
    4. Škrha J. Patogeneze diabetes mellitus 1. a 2. typu v roce 2011 - jednotící model poruchy glykoregulace. Vnitř Lék 2011; 57(11): 949-953. Go to PubMed...
    5. Schwartz SS, Epstein S, Corkey BE et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centri classification schema. Diabetes Care 2016; 39(2): 179-186. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-1585>. Go to original source... Go to PubMed...
    6. Basile KJ, Guy VC, Schwartz S et al. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep 2014; 14(11): 550. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892-014-0550-9>. Go to original source... Go to PubMed...
    7. Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am 2015; 99(1): 1-16. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mcna.2014.08.015>. Go to original source... Go to PubMed...
    8. Leslie RD, Palmer J, Schloot NC et al. Diabetes at the corssroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 2016; 59(1): 13-20. Go to original source... Go to PubMed...
    9. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773-795. Dostupné z DOI: <http://dx.doi.org/10.2337/db09-9028>. Go to original source... Go to PubMed...
    10. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1 and type 2 diabetes mellitus and obesity. Rev Endocrinol Metab Disord 2015; 16(1): 55-65. Dostupné z DOI: <http://dx.doi.org/10.1007/s11154-015-9309-0>. Go to original source... Go to PubMed...
    11. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G et al. Molecular and cellular mechanisms linking inflammation to insulin resistance and beta-cell dysfunction. Transl Res 2016; 167(1): 228-256. Dostupné z DOI: <http://dx.doi.org/1016/j.trsl.2015.08.011>. Go to original source... Go to PubMed...
    12. Subauste A, Gianani R, Chang AM et al. Islet autoimmunity identifies a unique pattern of impaired pancreatic beta-cell function, markedly reduced pancreatic beta-cell mass and insulin resistence in clinically diagnosed type 2 diabetes. PLoSOne 2014; 9(9): e106537. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0106537>. Go to original source... Go to PubMed...
    13. Maedler K, Carr RD, Bosco D et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90(1): 501-506. Go to original source... Go to PubMed...
    14. DelGuerra S, Grupillo M, Masini M et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diab Metab Res Rev 2007; 23(3): 234-238. Go to original source... Go to PubMed...
    15. Juhl CB, Porksen N, Hollingdal M et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care 2000; 23(5): 675-681. Go to original source... Go to PubMed...
    16. Matsuda T, Takahashi H, MiedaY et al. Regulation of pancreatic beta cell mass by cross-interaction between CCAAT enhancer binding protein beta induced by endoplasmic reticulum stress and AMP-activated protein kinase activity. PLoSOne 2015; 10(6): e0130757. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0130757>. Go to original source... Go to PubMed...
    17. Dai YL, Huang Su-Ling, Leng Y. AICAR and Metformin Exert AMPK-dependent Effects on INS-1E Pancreatic β-cell Apoptosis via Differential Downstream Mechanisms. Int J Biol Sci 2015; 11(11): 1272-1280. Dostupné z DOI: <http://dx.doi.org/10.7150/ijbs.12108>. Go to original source... Go to PubMed...
    18. Simon-Szabo L, Kokas M, Mandl J et al. Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS ONE 2014; 9(6): e97868. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0097868>. Go to original source... Go to PubMed...
    19. Saitoh Y, Chun-ping C, Noma K et al. Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. Diab Obes Metab 2008; 10(7): 564-573. Go to original source... Go to PubMed...
    20. Puddu A, Sanguineti R, Durante A et al. Pioglitazone attenuates the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T15. Regulatory Peptides 2012; 177(1-3): 79-84. Dostupné z DOI: <http://dx.doi.org/10.1016/j.regpep.2012.05.089>. Go to original source... Go to PubMed...
    21. Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diab Obes Metab 2008; 10(8): 617-625. Go to original source... Go to PubMed...
    22. Wang A, Li X, Zheng Y et al. Thiazolidinediones protect mouse pancreatic beta-cells directly from cytokine-induced cytotoxicity through PPAR gamma-dependent mechanisms. Acta Diabetol 2013; 50(2): 163-173. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592-010-0239-8>. Go to original source... Go to PubMed...
    23. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Molec Cell Endocrinol 2009; 297(1-2): 127-136. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mce.2008.08.012>. Go to original source... Go to PubMed...
    24. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidylpeptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146(5): 717-727. Go to original source... Go to PubMed...
    25. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55(6): 1695-1704. Go to original source... Go to PubMed...
    26. Chen J, Couto FM, Minn AH et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006; 346(3): 1067-1074. Go to original source... Go to PubMed...
    27. Shimoda M, Kanda Y, Hamamoto S et al. The guman glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011; 54(5): 1098-1108. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-011-2069-9>. Go to original source... Go to PubMed...
    28. Chang TJ, Tseng HC, Liu MW et al. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation. Sci Rep 2016; 6: 23403. Dostupné z DOI: <http://dx.doi.org/10.1038/srep23403>. Go to original source... Go to PubMed...
    29. Shah P, Ardestani A, Dharmadhikari G. et al. The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab 2013; 98(7): E1163-E1172. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-1029>. Go to original source... Go to PubMed...
    30. Kim JY, Lim DM, Park HS et al. Exendin-4 protects against sulfonylurea-induced beta-cell apoptosis. J Pharmacol Sci 2012; 118(1): 65-74. Go to original source... Go to PubMed...
    31. Cernea S, Raz I. Therapy in the early stage: Incretins. Diabetes Care 2011; 34(Supp 2): S264-S271. Dostupné z DOI: <http://dx.doi.org/10.2337/dc11-s223>. Go to original source... Go to PubMed...
    32. Hansen HH, Jelsing J, Hansen CF et al. The sodium glucose cotransporter Type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat. J Pharmacol Exp Therap 2014; 350(3): 657-664. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.114.213454>. Go to original source... Go to PubMed...
    33. Macdonald FR, Peel JE, Jones HB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diab Obes Metab 2010; 12(11): 1004-1012. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463-1326.2010.01291.x>. Go to original source... Go to PubMed...
    34. Okauchi S, Shimoda M, Obata A et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun 2016; 470(3): 772-782. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbrc.2015.10.109>. Go to original source... Go to PubMed...
    35. Jurczak MJ, Lee HY, Birkenfeld AL et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60(3): 890-898. Dostupné z DOI: <http://dx.doi.org/10.2337/db10-1328>. Go to original source... Go to PubMed...
    36. Cheng STW, Chen LH, Li SYT et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in Type 1 diabetes. PLoSOne 2016; 11(1): e0147391. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.014739>. Go to original source... Go to PubMed...
    37. Ogata H, Seino Y, Harada N et al. K-ATP channel as well as SGLT1participates in GIP secretion in the diabetic state. J Endocrinol 2014; 222(2): 191-200. Dostupné z DOI: <http://dx.doi.org/10.1530/JOE-14-0161>. Go to original source... Go to PubMed...
    38. Johnson JD, Bernal-Mizrachi E, Alejandro EU et al. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proc Nat Acad Sci US 2006; 103(51): 19575-19580. Go to original source... Go to PubMed...
    39. Kautz S, van Buerck L, Schuster M et al. Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2 C95S). Diabetologia 2012; 55(2): 382-391. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-011-2362-7>. Go to original source... Go to PubMed...
    40. Naik RG, Palmer JP. Preservation of beta-cell function in type 1 diabetes. Diabetes Rev 1999; 7(3): 154-182.
    41. Skyler JS. Prevention and reversal of type 1 diabetes - past challenges and future opportunities. Diabetes Care 2015; 38(6): 997-1007. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-0349>. Go to original source... Go to PubMed...
    42. Owens DR. Clinical evidence for the earlier initiation of insulin therapy in Type 2 diabetes. Diabetes Technol Therap 2013; 15(9): 776-785. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2013.0081>. Go to original source... Go to PubMed...
    43. Kikawa K, Sakano D, Shiraki N et al. Beneficial effect of insulin treatment on islet transplantation outcomes in Akita mice. PLoS ONE 2014; 9(4): e95451. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0095451>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.